Offering the Appropriate Patient the Opportunity for Treatment with TRK InhibitorsVideo Categories: NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.
Dr. Jennifer R. Brown talks about combining novel agents for treating CLL as the next step to achieve longer remissions for patients. Until now, novel agents have only been used individually or in combination with antibodies. New studies are being designed to measure the efficacy of combining novel agents with [ Read More ]
Dr. Sanjiv Agarwala identifies the newest developments in treatments for melanoma, cutaneous T-cell lymphoma, Merkel cell carcinoma, squamous-cell carcinoma, and invasive-cell carcinoma.